Crohn's Ileocolitis
Conditions
Keywords
Crohn disease, Immunotherapy, Helminth antigen
Brief summary
This multicenter phase 2 clinical trial is designed to assess safety of P28GST (protein 28 Kd glutathion S Transferrase), aiming to control inflammation in moderate Crohn's Disease (CD), before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from Schistosoma with potent immunogenic and anti-oxidant properties. Based on experimental evidence of its anti-inflammatory properties, the investigators hypothesized that administration of P28GST could protect against recurrence after intestinal resection surgery in CD.
Detailed description
To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study. CD patients will be included after intestinal resection surgery or in moderate Crohn's Disease (CD). Drug therapy will consisted in 3 injections of 100 µg of P28GST within 3 months (one injection per month). The main objective of this study is to follow-up monthly rate and seriousness of adverse events during one year. Secondary objectives are to control immunologic and inflammatory blood and tissue markers, appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index).
Interventions
DRUGP28GST
3 injections of 100 µg of P28GST within 3 months (one injection per month)
Sponsors
University Hospital, Lille
National Research Agency, France
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects between the ages of ≥18 years at inclusion. * Subjects with ileal or ileo-colic CD without fistula * Subjects operated or not * CDAI score \< 220 * no concomitant treatment excepted salicylates * Women of child bearing potential must be negative for pregnancy prior to study enrolment * contraceptive means : females of childbearing potential as well as males are required to use adequate contraceptive methods for 6 months starting at the inclusion, i;e 4 months after the 3rd injection . * No tobacco consumption (end date of tobacco consumption 8 days before surgery). * Signed consent form * French social security coverage.
Exclusion criteria
* Subject who use of azathioprine, anti-TNF (Tumor Necrosis Factor), methotrexate, Vedolizumab, Ustekinumab and other immunosuppressors for 8 weeks before first injection of P28GST * Subject who use of corticosteroids for 15 days before first injection of P28GST * Subject with history of vaccine hyper sensitivity or allergy. * Subject with any other clinical manifestation determined by the investigator * Subject wih AIDS, B or C hepatitis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants wtih adverse events as a measure of safety and tolerability | up to one year | Clinical and blood markers change from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Main immunologic and inflammatory blood and tissue markers. | up to one year | — |
| Appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index) and confirmed by a morphologic examination. | up to one year | — |
| Intestinal microbiota | at inclusion, at 4 month , at 12 month | Evolution of bacterial species by genomic analysis |
Countries
France
Contacts
STUDY_CHAIRDominique DEPLANQUE, MD, PhD
Lille University Hospital
Outcome results
None listed